Company Filing History:
Years Active: 2014
Title: Eli Moallem: Innovator in Immuno-Modulation
Introduction
Eli Moallem is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of immunology through his innovative research and patents. His work focuses on the modulation of immune responses, which has important implications for treating various immune-related disorders.
Latest Patents
Eli Moallem holds a patent for the invention titled "Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation." This patent describes the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, it relates to compounds that interact and bind to CAP1, particularly anti-CAP1 antibodies, for the treatment of immune-related disorders by modulating the Th1/Th2 balance. The invention also provides a screening method for immuno-modulatory compounds that interact with CAP1. He has 1 patent to his name.
Career Highlights
Eli Moallem has established himself as a key figure in the field of immunology. His work at Protab Ltd. has allowed him to explore innovative solutions for immune-related challenges. His research has the potential to lead to new therapeutic approaches that can significantly improve patient outcomes.
Collaborations
Eli collaborates with Yaakov Naparstek, a fellow researcher, to further advance their work in immuno-modulation. Their combined expertise enhances the potential for groundbreaking discoveries in the field.
Conclusion
Eli Moallem's contributions to immunology through his patent on CAP1 highlight his innovative spirit and dedication to advancing medical science. His work at Protab Ltd. and collaborations with other experts position him as a significant player in the quest for effective treatments for immune-related disorders.